Treatment for stable coronary artery disease: A network meta-analysis of cost-effectiveness studies

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Caruba, Thibaut ^a   Katsahian, Sandrine ^b,c   Schramm, Catherine ^b   Nelson, Anaïs Charles ^b   Durieux, Pierre ^a,c   Bégué, Dominique ^d   Juillière, Yves ^e   Dubourg, Olivier ^f,g   Danchin, Nicolas ^a,d   Sabatier, Brigitte ^a,c  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Cardiologie   (France)

^f HÔPITAL AMBROISE PARÉ   (France)

^g LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT;

ADULT; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DRUG COST; DRUG ELUTING STENT; FEMALE; FINANCIAL MANAGEMENT; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; OFF PUMP CORONARY SURGERY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RANDOMIZED CONTROLLED TRIAL; STANDARDIZATION; SYSTEMATIC REVIEW; ECONOMICS; PERCUTANEOUS CORONARY INTERVENTION;

CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; DRUG-ELUTING STENTS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION;

EID: 84902436214     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098371     Document Type: Article

References (49)

1. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, et al. (2012) 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 60: e44-e164. doi:10.1016/j.jacc.2012.07.013.
2. Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW (2011) Coronary revascularization trends in the United States, 2001-2008. JAMA J Am Med Assoc 305: 1769-1776. doi:10.1001/jama.2011.551.
3. Eisenberg MJ (2006) Drug-eluting stents: the price is not right. Circulation 114: 1745-1754; discussion 1754. doi:10.1161/CIRCULATIONAHA.106. 646190.
4. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, et al. (2009) Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 119: 3198-3206. doi:10.1161/CIRCULATIONAHA.108.826479.
5. Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, et al. (2012) Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv 5: 476-490. doi:10.1161/ CIRCINTERVENTIONS. 112.970954.
6. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, et al. (2009) Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 373: 1190-1197. doi:10.1016/S0140-6736(09) 60552-3.
7. Stergiopoulos K, Brown DL (2012) Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials. Arch Intern Med 172: 312-319. doi:10.1001/archinternmed.2011.1484.
8. Hlatky MA, Boothroyd DB, Baker L, Kazi DS, Solomon MD, et al. (2013) Comparative effectiveness of multivessel coronary bypass surgery and multivessel percutaneous coronary intervention: a cohort study. Ann Intern Med 158: 727-734. doi:10.7326/0003-4819-158-10-201305210-00639.
9. Hill RA, Boland A, Dickson R, Dündar Y, Haycox A, et al. (2007) Drug-eluting stents: a systematic review and economic evaluation. Health Technol Assess Winch Engl 11: iii, xi-221.
10. Weintraub WS, Mahoney EM, Zhang Z, Chu H, Hutton J, et al. (2004) One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial. Heart Br Card Soc 90: 782-788. doi:10.1136/hrt.2003.015057. (Pubitemid 38813640)
11. Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, et al. (2004) Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 110: 508-514. doi:10.1161/01.CIR.0000136821.99814.43. (Pubitemid 39031165)
12. Eisenstein EL, Wijns W, Fajadet J, Mauri L, Edwards R, et al. (2009) Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2: 1178-1187. doi:10.1016/j.jcin.2009. 10.011.
13. Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, et al. (1997) Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 336: 92-99. doi:10.1056/NEJM199701093360203. (Pubitemid 27020885)
14. Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, et al. (2008) Costeffectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes 1: 12-20. doi:10.1161/CIRCOUTCOMES.108.798462.
15. OED website. Available: http://www.oecd.org/std/prices-ppp/ (n.d.).
16. Bertoldi EG, Rohde LE, Zimerman LI, Pimentel M, Polanczyk CA (2011) Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: The perspective of a middle-income country's public health system. Int J Cardiol. doi:10.1016/j.ijcard.2011.06.046.
17. Kühr EM, Ribeiro RA, Rohde LEP, Polanczyk CA (2011) Cost-effectiveness of supervised exercise therapy in heart failure patients. Value Health J Int Soc Pharmacoeconomics Outcomes Res 14: S100-107. doi:10.1016/j.jval.2011.05.006.
18. Antioch KM, Jennings G, Botti M, Chapman R, Wulfsohn V (2002) Integrating cost-effectiveness evidence into clinical practice guidelines in Australia for acute myocardial infarction. Eur J Health Econ HEPAC Health Econ Prev Care 3: 26-39. doi:10.1007/s10198-001-0088-z. (Pubitemid 41214082)
19. Villanueva EV, Wasiak J, Petherick ES (2003) Percutaneous transluminal rotational atherectomy for coronary artery disease. Cochrane Database Syst Rev Online: CD003334. doi:10.1002/14651858.CD003334.
20. Evers S, Goossens M, de Vet H, van Tulder M, Ament A (2005) Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care 21: 240-245. (Pubitemid 40656554)
21. Woods BS, Hawkins N, Scott DA (2010) Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multiarm trials: a tutorial. BMC Med Res Methodol 10: 54. doi:10.1186/1471-2288- 10-54.
22. Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23: 3105-3124. doi:10.1002/sim.1875. (Pubitemid 39334902)
23. Higgins JP, Whitehead A (1996) Borrowing strength from external trials in a meta-analysis. Stat Med 15: 2733-2749. doi:10.1002/(SICI)1097-0258(19961230) 15:24〈2733::AID-SIM562〉3.0.CO;2-0. (Pubitemid 27011054)
24. Smith TC, Spiegelhalter DJ, Thomas A (1995) Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med 14: 2685-2699. (Pubitemid 26014258)
25. Lu G, Ades AE, Sutton AJ, Cooper NJ, Briggs AH, et al. (2007) Meta-analysis of mixed treatment comparisons at multiple follow-up times. Stat Med 26: 3681-3699. doi:10.1002/sim.2831. (Pubitemid 47307743)
26. Kinlay S (1996) Cost-effectiveness of coronary angioplasty versus medical treatment: the impact of cost-shifting. Aust N Z J Med 26: 20-26.
27. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, et al. (2001) Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344: 1117-1124. doi:10.1056/ NEJM200104123441502. (Pubitemid 32285232)
28. Legrand VMG, Serruys PW, Unger F, van Hout BA, Vrolix MCM, et al. (2004) Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 109: 1114-1120. doi:10.1161/01.CIR.0000118504.61212.4B. (Pubitemid 38332615)
29. Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, et al. (1998) Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 352: 673-681. (Pubitemid 28398701)
30. Weintraub WS, Mauldin PD, Becker E, Kosinski AS, King SB 3rd (1995) A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST). Circulation 92: 2831-2840.
31. Meredith I (n.d.) Trial updates & long term follow-up - ENDEAVOR I: 3-year, ENDEAVOR II: 2-year clinical results. May 16-19 2006 Eur Paris 2006.
32. Meredith I, Wijns W (n.d.) Clinical Trial Update. ENDEAVOR I & II clinical program: long term follow-up. 4 Sept 2005 ESC Stockh 2005.
33. Zeiher A (n.d.) ENDEAVOR clinical Program Update. ENDEAVOR I: 4-year clinical follow-up. ENDEAVOR II: 3-year clinical follow-up. May 22 2007 Eur Barc 2007.
34. Rodriguez A, Boullon F, Perez-Baliño N, Paviotti C, Liprandi MI, et al. (1993) Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. ERACI Group. J Am Coll Cardiol 22: 1060-1067. (Pubitemid 23285755)
35. Rodriguez A, Mele E, Peyregne E, Bullon F, Perez-Baliño N, et al. (1996) Three-year follow-up of the Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease (ERACI). J Am Coll Cardiol 27: 1178-1184. (Pubitemid 26117710)
36. Favarato D, Hueb W, Gersh BJ, Soares PR, Cesar LAM, et al. (2003) Relative cost comparison of treatments for coronary artery disease: the First Year Follow-Up of MASS II Study. Circulation 108 Suppl 1: II21-23. doi:10.1161/01.cir.0000087381.98299.7b. (Pubitemid 37099924)
37. Van Hout BA, Serruys PW, Lemos PA, van den Brand MJBM, van Es G-A, et al. (2005) One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial. Heart Br Card Soc 91: 507-512. doi:10.1136/hrt.2004.034454. (Pubitemid 40432784)
38. Sculpher M, Smith D, Clayton T, Henderson R, Buxton M, et al. (2002) Coronary angioplasty versus medical therapy for angina. Health service costs based on the second Randomized Intervention Treatment of Angina (RITA-2) trial. Eur Heart J 23: 1291-1300. (Pubitemid 35238511)
39. Cohen DJ, Krumholz HM, Sukin CA, Ho KK, Siegrist RB, et al. (1995) Inhospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators. Circulation 92: 2480-2487.
40. Cohen DJ, Lavelle TA, Van Hout B, Li H, Lei Y, et al. (2012) Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: one-year results from the SYNTAX trial. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv 79: 198-209. doi:10.1002/ccd.23147.
41. Bakhai A, Stone GW, Mahoney E, Lavelle TA, Shi C, et al. (2006) Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. J Am Coll Cardiol 48: 253-261. doi:10.1016/j.jacc.2006.02.063. (Pubitemid 44026660)
42. Schömig A, Mehilli J, de Waha A, Seyfarth M, Pache J, et al. (2008) A metaanalysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. J Am Coll Cardiol 52: 894-904. doi:10.1016/j.jacc.2008.05.051.
43. Eisenstein EL, Leon MB, Kandzari DE, Mauri L, Edwards R, et al. (2009) Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2: 1199-1207. doi:10.1016/j.jcin.2009.10.009.
44. Hlatky MA, Boothroyd DB, Melsop KA, Kennedy L, Rihal C, et al. (2009) Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Circulation 120: 2550-2558. doi:10.1161/ CIRCULATIONAHA.109.912709.
45. Gudnason T, Gudnadottir GS, Lagerqvist B, Eyjolfsson K, Nilsson T, et al. (2013) Comparison of interventional cardiology in two European countries: a nationwide internet based registry study. Int J Cardiol 168: 1237-1242. doi:10.1016/j.ijcard.2012.11.054.
46. Puymirat E, Blanchard D, Perier M-C, Piadonataccio M, Gilard M, et al. (2013) Study Design and Baseline Characteristics of the National Observational Study of Diagnostic and Interventional Cardiac Catheterization by the French Society of Cardiology. Am J Cardiol. doi:10.1016/j.amjcard.2013.03.030.
47. Díaz JF, de La Torre JM, Sabaté M, Goicolea J (2012) Spanish Cardiac Catheterization and Coronary Intervention Registry. 21st official report of the Spanish Society of Cardiology Working Group on Cardiac Catheterization and Interventional Cardiology (1990-2011). Rev Esp Cardiol Engl Ed 65: 1106-1116. doi:10.1016/j.recesp.2012.07.021.
48. Dehmer GJ, Weaver D, Roe MT, Milford-Beland S, Fitzgerald S, et al. (2012) A contemporary view of diagnostic cardiac catheterization and percutaneous coronary intervention in the United States: a report from the CathPCI Registry of the National Cardiovascular Data Registry, 2010 through June 2011. J Am Coll Cardiol 60: 2017-2031. doi:10.1016/j.jacc.2012.08.966.
49. Reed SD, Anstrom KJ, Bakhai A, Briggs AH, Califf RM, et al. (2005) Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J 149: 434-443. doi:10.1016/j.ahj.2004.11.001. (Pubitemid 40585405)